• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Clene Inc. - Common Stock (NQ:CLNN)

    4.090 -0.110 (-2.62%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 18, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 73,354
    Open 4.190
    Bid (Size) 4.080 (200)
    Ask (Size) 4.500 (2,000)
    Prev. Close 4.200
    Today's Range 4.080 - 4.469
    52wk Range 3.640 - 13.50
    Shares Outstanding 128,404,735
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS ↗
    Clene (NASDAQ:CLNN) said it is preparing to submit a new drug application, or NDA, in early fourth quarter for CNM-Au8 as a potential treatment for amyotrophic lateral sclerosis, following a series of... 
    Via MarketBeat
    MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
    Via Investor Brand Network

    Performance

    YTD
    -29.1%
    -29.1%
    1 Month
    -28.6%
    -28.6%
    3 Month
    -39.8%
    -39.8%
    6 Month
    -3.1%
    -3.1%
    1 Year
    -3.5%
    -3.5%

    More News

    Read More
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
    Via Benzinga
    News headline image
    Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
    From BioMedWire
    Via GlobeNewswire
    Landmark Study Shows How Menopause Influences the Symptoms of Multiple Sclerosis
    Via Investor Brand Network
    BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Positive REPAIR-MS Results at ECTRIMS 2025
    Via Investor Brand Network
    New Smart Pen Shows 96% Efficacy in Detecting Parkinson’s Disease
    Via Investor Brand Network
    Clene Inc.’s (NASDAQ: CLNN) Lead Candidate CNM-Au8(R) Shows Promise in Improving Cellular Health in Parkinson’s Disease
    Via Investor Brand Network
    MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Advances Toward NDA Submission for ALS Therapy
    Via Investor Brand Network
    BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Preclinical Data Showing CNM-Au8 Improves Cellular Health in Parkinson’s Disease Model
    Via Investor Brand Network
    Research Uncovers Possible Way to Repair Myelin in MS Patients
    Via Investor Brand Network
    BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at H.C. Wainwright Global Investment Conference
    Via Investor Brand Network
    InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Builds Late-Stage Momentum in Neuro Pipeline
    Via Investor Brand Network
    Pioneering Therapy Could Slow the Effects of Aging
    Via Investor Brand Network
    Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results as Company Prepares for NDA Submission and Extends Runway into 2026
    Via Investor Brand Network
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results, Targets Year-End NDA Submission for ALS Therapy
    Via Investor Brand Network
    News headline image
    Clene Posts 70% Revenue Drop in Q2 ↗
    Via The Motley Fool
    InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present Corporate Update at Emerging Growth Conference on Aug. 20
    Via Investor Brand Network
    Parkinson’s-Gut Bacteria Link Suggests Surprisingly Simple Treatment Option
    Via Investor Brand Network
    BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) to Present at Canaccord 45th Annual Growth Conference
    Via Investor Brand Network
    New AI-Based Speech Tool Detects Possibility of Parkinson’s Disease
    Via Investor Brand Network
    Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate
    Via Investor Brand Network
    BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Builds Momentum to Bring New Hope to Neuro Patients
    Via Investor Brand Network

    Frequently Asked Questions

    Is Clene Inc. - Common Stock publicly traded?
    Yes, Clene Inc. - Common Stock is publicly traded.
    What exchange does Clene Inc. - Common Stock trade on?
    Clene Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Clene Inc. - Common Stock?
    The ticker symbol for Clene Inc. - Common Stock is CLNN on the Nasdaq Stock Market
    What is the current price of Clene Inc. - Common Stock?
    The current price of Clene Inc. - Common Stock is 4.090
    When was Clene Inc. - Common Stock last traded?
    The last trade of Clene Inc. - Common Stock was at 08/18/26 04:00 PM ET
    What is the market capitalization of Clene Inc. - Common Stock?
    The market capitalization of Clene Inc. - Common Stock is 525.18M
    How many shares of Clene Inc. - Common Stock are outstanding?
    Clene Inc. - Common Stock has 525M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.